Our finding that single‐pattern cytoplasmic BAP1 is associated with improved survival of patients with non‐epithelioid MPM suggests that BAP1 IHC may also be useful as a prognostic biomarker, as has been suggested for glioma [52]. This evidence concerns the gene BAP1 and central nervous system cancer.